Cheapest Private Semaglutide - UK Price From £69.00

Our Pricing

Private Semaglutide Prescription - Order Today

Published on: June 03, 2026

Securing a private semaglutide prescription UK through Cured Pharmacy takes under three minutes with our online clinical assessment. Our UK-registered prescribers evaluate your suitability for semaglutide weight loss treatment, with genuine Wegovy available from £79.00 and discreet next-day delivery across the UK.

How Semaglutide Works for Weight Loss

Semaglutide belongs to a class of medications called GLP-1 receptor agonists, originally developed for type 2 diabetes management but now licensed by the MHRA for chronic weight management in adults with obesity or overweight with weight-related conditions [1]. The medication mimics glucagon-like peptide-1, a natural hormone that regulates appetite and food intake by acting on receptors in the brain, stomach, and pancreas.

In the landmark STEP 1 trial involving 1,961 adults without diabetes, participants receiving once-weekly semaglutide 2.4mg achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [2]. The medication slows gastric emptying, increases feelings of fullness after meals, and reduces hunger signals between meals, making it easier to adhere to reduced-calorie eating patterns.

Clinical data shows semaglutide also improves several cardiometabolic risk factors beyond weight reduction, including blood pressure, lipid profiles, and inflammatory markers [2]. These benefits may contribute to long-term health outcomes in patients with obesity-related complications, though semaglutide is not a cure and requires ongoing treatment to maintain weight loss.

Getting a Private Semaglutide Prescription UK: The Process

Unlike NHS pathways that may involve months-long waiting lists and strict BMI thresholds, a private prescription route through Cured Pharmacy offers same-day assessment by UK-registered prescribers. Our clinical team, overseen by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), evaluates your medical history, current medications, and weight loss goals through a comprehensive online questionnaire.

The assessment takes under three minutes to complete and covers essential safety screening including cardiovascular history, previous weight loss attempts, thyroid conditions, and family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 — both contraindications for semaglutide use [3]. Our prescribers also assess for potential drug interactions and evaluate whether you meet NICE guidance criteria for GLP-1 receptor agonist therapy.

Once approved, your prescription is processed by our GPhC-registered pharmacy (9012511) and dispensed with genuine UK-licensed Wegovy pens. We provide full injection training materials, dosing schedules, and ongoing clinical support throughout your treatment journey. All packaging is 100% discreet with no external pharmacy branding or medication details visible.

Who Qualifies for Private Semaglutide Prescription

NICE guidance recommends GLP-1 receptor agonists for adults with a BMI of 30 kg/m² or above, or 27 kg/m² with at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease [4]. Our prescribers follow these evidence-based thresholds when evaluating suitability, though final prescribing decisions account for individual patient circumstances and contraindications.

Semaglutide is contraindicated in pregnancy, breastfeeding, personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and severe gastrointestinal disease [3]. Patients with a history of pancreatitis, diabetic retinopathy complications, or severe renal impairment require careful evaluation before treatment initiation.

Wegovy Dosing Schedule and What to Expect

Wegovy follows a structured dose-escalation protocol designed to minimise gastrointestinal side effects while optimising weight loss efficacy. Treatment begins with 0.25mg once weekly for four weeks, then increases monthly through 0.5mg, 1mg, and 1.7mg doses before reaching the maintenance dose of 2.4mg weekly [1]. This gradual titration allows your digestive system to adapt to semaglutide's effects on gastric emptying.

Each Wegovy pen contains four pre-filled doses for one month of treatment at the specified strength. The subcutaneous injection is administered once weekly on the same day each week, into the abdomen, thigh, or upper arm. Most patients find the injection process straightforward after the first few doses, with minimal discomfort reported in clinical trials.

Common side effects during dose escalation include nausea, diarrhoea, constipation, vomiting, and abdominal pain, typically mild to moderate in severity and diminishing over time [2]. In STEP trials, approximately 7% of participants discontinued treatment due to gastrointestinal adverse events, compared to 3% in placebo groups. Staying well-hydrated, eating smaller meals, and avoiding high-fat foods can help manage these effects during the initial weeks.

Monitoring and Ongoing Support

Effective semaglutide treatment requires regular monitoring of weight loss progress, side effect management, and adjustment of lifestyle interventions. Our clinical team recommends tracking your weight fortnightly during the first three months, then monthly once you reach maintenance dosing. If you achieve less than 5% weight loss after 12 weeks at the maintenance dose, your prescriber may reassess treatment suitability.

We provide ongoing prescription renewals through follow-up consultations every three months, ensuring your treatment remains appropriate and effective. This regular clinical oversight aligns with MHRA guidance on long-term GLP-1 therapy and allows early identification of any emerging safety concerns or reduced treatment response.

Private Semaglutide Prescription Cost and Transparent Pricing

At Cured Pharmacy, Wegovy (semaglutide 2.4mg) is available from £79.00 per month, with pricing visible before you complete your clinical assessment — no hidden fees or surprise charges after prescription approval. This transparent approach contrasts with some providers who only reveal costs after lengthy consultations.

Your total monthly cost includes the medication, UK prescriber consultation, pharmacy dispensing fee, and discreet delivery. We guarantee the lowest prices in the UK for genuine, MHRA-licensed semaglutide, sourced directly from licensed wholesalers with full cold-chain integrity maintained throughout storage and dispatch.

Many patients find private prescription costs comparable to or lower than typical NHS prescription charges when accounting for multiple items, with the significant advantage of immediate access without waiting lists. Treatment duration varies by individual, but clinical trials suggest maintaining semaglutide therapy for at least 12-18 months optimises sustained weight loss outcomes [2].

Semaglutide vs Other Weight Loss Treatments

The UK market offers several prescription weight loss medications, each with distinct mechanisms, efficacy profiles, and administration methods. Semaglutide (Wegovy) represents the current gold standard among GLP-1 receptor agonists for weight management, demonstrating superior weight loss compared to earlier agents like liraglutide (Saxenda) in head-to-head trials [5].

Orlistat, available as branded Xenical or generic formulations, works by blocking fat absorption in the digestive tract rather than affecting appetite hormones. While effective for some patients, orlistat typically produces more modest weight loss (average 3-5% body weight) and requires strict dietary fat restriction to avoid gastrointestinal side effects [6]. The medication suits patients who prefer oral tablets over injections but may not achieve the magnitude of weight reduction seen with GLP-1 therapies.

Newer dual-action medications like tirzepatide (Mounjaro) activate both GLP-1 and GIP receptors, producing even greater average weight loss than semaglutide in clinical trials — up to 22.5% body weight reduction at the highest dose in SURPASS-3 [7]. However, tirzepatide currently holds UK licensing only for type 2 diabetes, not weight management, though this may change as regulatory submissions progress. Your prescriber will recommend the most appropriate treatment based on your medical profile, weight loss goals, and individual circumstances.

Combining Semaglutide with Lifestyle Interventions

Clinical trial protocols for semaglutide included structured lifestyle interventions comprising reduced-calorie diet (500 kcal daily deficit) and increased physical activity (150 minutes weekly of moderate exercise) [2]. These combined approaches produced the weight loss outcomes reported in STEP trials, and medication alone without behaviour modification typically yields suboptimal results.

We provide comprehensive lifestyle guidance alongside your prescription, including evidence-based nutrition strategies, physical activity progression plans, and behavioural techniques to support long-term weight management. Semaglutide facilitates adherence to these interventions by reducing hunger and cravings, making sustainable lifestyle changes more achievable for many patients.

Safety Considerations and When to Seek Medical Advice

While semaglutide demonstrates a well-established safety profile from extensive clinical trial data and real-world use, certain adverse effects require prompt medical attention. Severe persistent abdominal pain, especially if radiating to the back and accompanied by vomiting, may indicate pancreatitis — a rare but serious side effect requiring immediate assessment [3]. Similarly, symptoms of thyroid nodules such as a lump in the neck, persistent hoarseness, or difficulty swallowing warrant urgent evaluation.

Semaglutide can increase heart rate by 2-10 beats per minute in some patients, and those with pre-existing cardiovascular conditions should have regular pulse and blood pressure monitoring [1]. Hypoglycaemia risk increases if semaglutide is used alongside other glucose-lowering medications, particularly sulfonylureas or insulin, requiring dose adjustments of these concurrent treatments.

Gallbladder-related events including cholelithiasis and cholecystitis occurred more frequently with semaglutide than placebo in clinical trials, likely related to rapid weight loss rather than direct drug effects [2]. Patients experiencing severe right upper quadrant pain, fever, or jaundice should seek medical assessment. Our clinical team at Cured Pharmacy remains available for safety concerns throughout your treatment, with Superintendent Pharmacist Tarun Kumar providing expert oversight of all prescribing decisions.

Women of childbearing potential should use effective contraception during semaglutide treatment and discontinue the medication at least two months before planned pregnancy, as GLP-1 receptor agonists are contraindicated in pregnancy due to limited human safety data [3]. If you become pregnant while taking semaglutide, stop treatment immediately and contact your prescriber or GP for alternative weight management strategies.

Scientific References

1. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Medicines and Healthcare products Regulatory Agency. (2023). Semaglutide (Wegovy): Risk of thyroid C-cell tumours and acute pancreatitis. Drug Safety Update, 16(9). https://www.gov.uk/drug-safety-update [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE Technology Appraisal Guidance. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
5. Rubino, D. M., Greenway, F. L., Khalid, U., O'Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., & Garvey, W. T. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes. JAMA, 327(2), 138–150. https://doi.org/10.1001/jama.2021.23619 [accessed 13 August 2026]
6. National Institute for Health and Care Excellence. (2014). Obesity: identification, assessment and management [CG189]. NICE Clinical Guideline. https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]
7. Ludvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet, 398(10300), 583–598. https://doi.org/10.1016/S0140-6736(21)01443-4 [accessed 13 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.